| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9054 | Bortezomib (boruzu) | Boruzu | 0.1mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2024 | Mar 26, 2025 | In Use | ||
| J9015 | Aldesleukin | Proleukin | Per single vial (1 vial = 22 million IU) | Immunotherapy | Cytokine | Interleukin-2 | No | 1992 | Oct 1, 1996 | In Use | ||
| J9120 | Dactinomycin | Cosmegen | 0.5 mg | Chemotherapy | Antitumor Antibiotic | Carboxylic Acids and Amino Acids/Peptides | No | 1964 | Jan 1, 1984 | In Use | ||
| NA | Gardasil-9 | Human papillomavirus vaccine | Ancillary Therapy | Protective Agent | HPV Vaccine | No | 2016 | In Use | ||||
| N/A | Dordaviprone | MODEYSO | 125mg | Chemotherapy | Protease Activator | ClpP, dopamine D2 | Yes | 2025 | In Use | |||
| J9227 | Isatuximab-irtc | Sarclisa | 10mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2020 | Oct 1, 2020 | In Use | ||
| J8705 | Topotecan | Hycamtin | 0.25 mg | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | Yes | 1996 | Jan 1, 2009 | In Use | ||
| J1626 | Granisetron Hydrochloride | Granisol [DSC], Sancuso, Sustol, Kytril | 100 mcg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 1993 | Jan 1, 2009 | In Use | ||
| J8522 | Capecitabine | Multiple | 50mg | Chemotherapy | Antimetabolite | Yes | 2005 | Sep 11, 2024 | In Use | |||
| NA | Umbralisib | Ukoniq | 260.2mg | Chemotherapy | Enzyme Inhibitor | PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 | Yes | 2021 | In Use | |||
| NA | Dasatinib | Sprycel | 20 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
| J9225 | Histrelin Acetate | Vantas | 50 mg | Hormonal Therapy | GnRH Agonist | No | 2004 | Jan 1, 2008 | In Use | |||
| NA | Cortisone Acetate | Cortisone Acetate | 25 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1951 | In Use | |||
| J9072 | Cyclophosphamide (frindovyx) | Frindovyx | 5mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2025 | Sep 8, 2025 | In Use | ||
| NA | Sotorasib | Lumakras | Multiple | Chemotherapy | RAS Inhibitor | KRASG12C | Yes | 2021 | In Use | |||
| NA | Elacestrant | Orserdu | Multiple | Hormonal Therapy | Estrogen Receptor Antagonist | ERɑ | Yes | 2023 | In Use | |||
| NA | Vandetanib | Caprelsa | 300 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, EGFR | Yes | 2011 | In Use | |||
| NA | Erdafitinib | Balversa | 3mg, 4mg, 5mg | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR1, FGFR2, FGFR3, FGFR4 | Yes | 2019 | In Use | |||
| Q5129 | Bevacizumab-adcd | Vegzelma | 10mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2023 | Mar 17, 2023 | In Use | ||
| NA | idelalisib | Zydelig | 150 mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2014 | In Use | |||
| NA | Cyclophosphamide | Cyclophosphamide oral | 50 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1959 | In Use | |||
| J2405 | Ondansetron | Zofran, Zofran ODT, Zuplenz | 1 mg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 1991 | Jan 1, 1993 | In Use | ||
| NA | Avapritinib | Ayvakit | 300mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
| J9064 | Cabazitaxel (Sandoz) | Cabazitaxel | 1mg | Chemotherapy | Antimitotic Agent | Taxane | No | 2023 | Aug 28, 2023 | In Use | ||
| J9285 | Olaratumab | Lartruvo | 10 mg | Immunotherapy | Monoclonal Antibody | PDGFR | No | 2016 | Apr 1, 2017 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home